These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35732409)

  • 21. Anaplastic large cell lymphoma, ALK-positive.
    Ferreri AJ; Govi S; Pileri SA; Savage KJ
    Crit Rev Oncol Hematol; 2012 Aug; 83(2):293-302. PubMed ID: 22440390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
    Shustov A; Soma L
    Cancer Treat Res; 2019; 176():127-144. PubMed ID: 30596216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents.
    Rigaud C; Knörr F; Brugières L; Woessmann W
    Best Pract Res Clin Haematol; 2023 Mar; 36(1):101444. PubMed ID: 36907641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful combination of crizotinib and hematopoietic stem cell transplantation in relapsed ALK-positive ALCL.
    Sun X; Fang X; Jiang Y
    Indian J Cancer; 2021; 58(1):108-111. PubMed ID: 33402581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brentuximab Vedotin and High-dose Methotrexate Administrated Alternately for Refractory Anaplastic Large-cell Lymphoma With Central Nervous System Disease.
    Mitsunobu T; Nishikawa T; Kusuda M; Nakagawa S; Kodama Y; Okamoto Y; Kawano Y
    J Pediatr Hematol Oncol; 2020 Aug; 42(6):e456-e458. PubMed ID: 31274669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful allogeneic stem cell transplantation for an adult with refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Chen CH; Chen SW; Shen WL; Chen TY; Tsao CJ; Huang WT
    Int J Hematol; 2007 Feb; 85(2):105-7. PubMed ID: 17321986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report.
    Woessmann W; Peters C; Lenhard M; Burkhardt B; Sykora KW; Dilloo D; Kremens B; Lang P; Führer M; Kühne T; Parwaresch R; Ebell W; Reiter A
    Br J Haematol; 2006 Apr; 133(2):176-82. PubMed ID: 16611309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The biology and management of systemic anaplastic large cell lymphoma.
    Hapgood G; Savage KJ
    Blood; 2015 Jul; 126(1):17-25. PubMed ID: 25869285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
    Domingo-Domènech E; Boumendil A; Climent F; Socié G; Kroschinsky F; Finel H; Vandenbergue E; Nemet D; Stelljes M; Bittenbring JT; Robinson S; Montoto S; Sureda A; Dreger P;
    Bone Marrow Transplant; 2020 Mar; 55(3):633-640. PubMed ID: 31695173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma.
    Cleary JM; Rodig S; Barr PM; Shinagare AB; Clark JW; Shapiro GI; Armand P
    J Natl Compr Canc Netw; 2014 Mar; 12(3):323-6; quiz 326. PubMed ID: 24616538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment of relapsed anaplastic large cell lymphoma with vinblastine monotherapy and allo-HSCT with reduced intensity conditioning regimen.
    Miyagaki S; Imamura T; Okumura Y; Ito I; Fujiki A; Osone S; Ishida H; Hosoi H
    Pediatr Int; 2015 Aug; 57(4):791-4. PubMed ID: 25847601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report.
    Harrer DC; Menhart K; Mayer S; Herr W; Reichle A; Vogelhuber M
    Front Oncol; 2020; 10():585830. PubMed ID: 33134180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recurrent ALK-negative anaplastic large T-cell lymphoma presenting as necrotizing vasculitis.
    Nambudiri VE; Aboutalebi A; Granter SR; Saavedra A
    Am J Dermatopathol; 2013 Jun; 35(4):512-6. PubMed ID: 23291583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Allogeneic hematopoietic stem cell transplantation following treatment with brentuximab vedotin for refractory Hodgkin lymphoma].
    Yamane Y; Koda Y; Kohashi S; Kato J; Hashida R; Sakurai M; Toyama T; Kikuchi T; Okayama M; Kasahara H; Karigane D; Shimizu T; Okamoto S; Mori T
    Rinsho Ketsueki; 2017; 58(7):755-759. PubMed ID: 28781270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adult systemic anaplastic large-cell lymphoma: recommendations for diagnosis and management.
    Bennani-Baiti N; Ansell S; Feldman AL
    Expert Rev Hematol; 2016; 9(2):137-50. PubMed ID: 26581318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ALK-positive primary cutaneous T-cell-lymphoma (CTCL) with unusual clinical presentation and aggressive course.
    Wehkamp U; Oschlies I; Nagel I; Brasch J; Kneba M; Günther A; Klapper W; Weichenthal M
    J Cutan Pathol; 2015 Nov; 42(11):870-7. PubMed ID: 26053561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of a TRAF1-ALK fusion in an anaplastic large cell lymphoma patient with chemotherapy and ALK inhibitor-resistant disease.
    Lawrence K; Berry B; Handshoe J; Hout D; Mazzola R; Morris SW; Saltman DL
    BMC Res Notes; 2015 Jul; 8():308. PubMed ID: 26187744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.
    Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Blaise D; Peggs KS; Afanasyev B; Diez-Martin JL; Corradini P; Michonneau D; Robinson S; Gutiérrez García G; Bonifazi F; Yakoub-Agha I; Gülbas Z; Bloor A; Delage J; Esquirol A; Malladi R; Scheid C; El-Cheikh J; Ghesquières H; Montoto S; Dreger P; Sureda A
    Cancer; 2019 Jan; 125(1):90-98. PubMed ID: 30351488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brentuximab vedotin (SGN-35) in a 3-year-old child with relapsed systemic anaplastic large cell lymphoma.
    Mikles B; Levine J; Gindin T; Bhagat G; Satwani P
    J Pediatr Hematol Oncol; 2014 Mar; 36(2):e85-7. PubMed ID: 23588340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study.
    Morel A; Brière J; Lamant L; Loschi M; Haioun C; Delarue R; Tournilhac O; Bachy E; Sonet A; Amorim S; Laurent C; Gaulard P; Tilly H; Sibon D
    Eur J Cancer; 2017 Sep; 83():146-153. PubMed ID: 28735072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.